Andrew J. Armstrong, Md

This study tests a mix of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer. The goal is to see if the combination can stop or slow the cancer from growing. Participants receive up to 10 cycles of the combo, th…